1099.HK
Strong BuyUnloved QualitySinopharm Group Co. Ltd. · Healthcare · China · $5.9B
HKD 14.92 +1.4% · close 6 Oct · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SINOPHARM GROUP CO. LTD.
Read
Sinopharm Group Co. Ltd. is China's largest pharmaceutical and healthcare products distributor, also engaged in retail pharmacy, manufacturing, and R&D. Its dominant market position as a state-backed entity, coupled with an extensive distribution network across China, provides a significant competitive advantage. The company is the largest pharmaceutical and healthcare product distributor in China, with significant vertical integration.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 611.1B | 647.5B | 699.6B | 685.5B | 674.5B | 2.5% | 669.4B | 683.4B | 710.4B | 2.6% |
| EPS (HKD) | 2.92 | 7.45 | 7.91 | 6.16 | 6.25 | 20.9% | 2.66 | 6.46 | 6.95 | 5.5% |
| Shares | 3.1B | 1.3B | 1.3B | 1.3B | 1.3B | -57.0% | 1.3B | — | — | — |
| Debt | 80.2B | 81.6B | 86.5B | 89.6B | 83.2B | 0.9% | 95.2B | — | — | — |
| Equity | 72.6B | 79.8B | 87.5B | 92.5B | 98.5B | 7.9% | — | — | — | — |
| Op CF | 10.9B | 24.6B | 20.1B | 13.5B | 16.6B | 11.0% | 28.7B | — | — | — |
| Inv CF | -1.5B | -4.2B | -1.1B | -4.4B | -1.1B | — | — | — | — | — |
| Fin CF | -17.2B | -6.7B | -9.0B | -20.3B | -21.9B | — | — | — | — | — |
Calmer than 89% of stocks we rank over the past year (21% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1099.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1099.HK | Sinopharm Group Co. Ltd.(you) | $5.9B | 88 | Strong Buy |
| 601607.SS | Shanghai Pharmaceuticals Holding Co., Ltd | $8.8B | 88 | Strong Buy |
| 600511.SS | China National Medicines Corporation Ltd. | $2.9B | 91 | Strong Buy |
| 000028.SZ | China National Accord Medicines Corporation Ltd. | $1.8B | 91 | Strong Buy |
| 0874.HK | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.7B | 75 | Buy |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.6B | 68 | Buy |
| 603368.SS | Guangxi LiuYao Group Co., Ltd | $898M | 85 | Strong Buy |
| 301015.SZ | Qingdao Baheal Medical INC. | $2.0B | 66 | Buy |
| 600056.SS | China Meheco Group Co., Ltd. | $2.0B | 63 | Hold |
| 600739.SS | Liaoning Cheng Da Co., Ltd. | $2.3B | 57 | Hold |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 53.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.